Minocycline safety and tolerability in huntington disease

Huntington study group

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.

Original languageEnglish (US)
Pages (from-to)547-549
Number of pages3
Issue number3
StatePublished - Aug 10 2004

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Minocycline safety and tolerability in huntington disease'. Together they form a unique fingerprint.

Cite this